Re: FOI 24/265 - Missing PAR Prednisolone 5mg Tablets

FOILicensing <FOILicensing@mhra.gov.uk>

Wed 27/03/2024 19:03

Dear

Regarding your request for the Public Assessment Report (PAR) for Prednisolone 5mg Tablets (PL 00142/0842), this marketing authorisation was granted by a Change of Authorisation Holder (CoA) on 02 June 2016. The original marketing authorisation for this product (PL 24668/0297) was granted by a decentralised procedure with the UK as Reference Member State (RMS).

A link to this PAR is provided below:

https://mhraproducts4853.blob.core.windows.net/docs/16dbd2f4f0518966d13f9208006fe831 f7a83eac

If you have a query about the information provided, please reply to this email.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Yours sincerely,

FOI Team, MHRA

From:

Sent: Thursday, March 14, 2024 1:28 PM

To: MHRA Customer Services < MHRACustomer Services @mhra.gov.uk >

Subject: Missing PAR

Good Afternoon,

I can find the SPC and PIL for the following on your website but not the Public Assessment Report. Is the PAR available for this product?

Prednisolone 5mg Tablets Accord-UK Ltd PL00142/0842

## Kind regards, and are intended only for the This electronic mail message and any attached files are the property of addressee indicated in the message. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon this information by persons or entities, other than the intended recipient is prohibited. If you received this in error, please contact the sender. Please note that any views, opinions or advice contained in this communication are those of the sending individual and not necessarily those of accepts no liability for any loss or damage which may be caused by software viruses.

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click **DHTermsAndConditions**